News

January 12, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) reports continued progress toward the filing of the 2017 Audited Financial Statements. During this process Alliance Growers continues to work on its projects and is looking forward to disclosing key new developments as they unfold. These new developments, along with new key relationships in the Cannabis space, will continue to grow and advance the Company, providing value to all its shareholders.

On January 8, 2018 the Company disclosed that the filings of the Company’s audited annual financial statements for the fiscal year ended August 31, 2017, the related management’s discussion and analysis and the certification of the annual filings for the year ended August 31, 2017 (collectively, the “2017 Annual Financial Statements”) were not completed by the deadline of December 29, 2017. As a result, the British Columbia Securities Commission issued a cease trade order (the “Cease Trade Order”) against the Company and securities have been halted from trading on the Canadian Securities Exchange (“CSE”).

The Company continues to progress with its auditors to file the 2017 Annual Financial Statements, which the Company expects to be completed soon, and Alliance will resume trading.  Once the 2017 Annual Financial Statements are filed, the Company will apply to have the Cease Trade Order revoked.

The Company wishes to thank investors for their support and patience as it progresses during this exciting time for the cannabis industry. Despite this temporary trading halt, Alliance expects a significant growth year in 2018.

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has finalized its a new business partnership with WFS Pharmagreen Inc., to jointly develop and operate a 40,000-square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Alliance Growers has entered into an exclusive agreement to acquire a late stage licensed producer applicant, Biotech Canna, to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec.  Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license.

This acquisition allows the company an opportunity to become a licensed producer in the province of Quebec and gain an in-road to provide tissue culture plantlets to all licensed producers in Quebec.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

On behalf of the board of directors of

ALLIANCE GROWERS CORP.

“Dennis Petke”

Dennis Petke

President and CEO

For more information contact:

Dennis Petke

Tel: 778-331-4266

DennisPetke@alliancegrowers.com

Rob Grace

Communications Consultant

Tel: 778-998-5431

RobDGrace@gmail.com

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

 

 

 


January 8, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”)  discloses today that the filings of the Company’s audited annual financial statements for the fiscal year ended August 31, 2017, the related management’s discussion and analysis and the certification of the annual filings for the year ended August 31, 2017 (collectively, the “2017 Annual Financial Statements”) were not completed by the deadline of December 29, 2017. As a result, the British Columbia Securities Commission issued a cease trade order (the “Cease Trade Order”) against the Company and securities have been halted from trading on the Canadian Securities Exchange (“CSE”).

The Company is actively working with its auditors to file the 2017 Annual Financial Statements, which the Company expects to be completed imminently. Once the 2017 Annual Financial Statements are filed, the Company will seek to have the Cease Trade Order revoked. The Company will be forthcoming with an update on the 2017 Annual Financial Statements once the required filings have been made.

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has finalized its a new business partnership with WFS Pharmagreen Inc., to jointly develop and operate a 40,000-square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Alliance Growers has entered into an exclusive agreement to acquire a late stage licensed producer applicant, Biotech Canna, to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec.  Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license.

This acquisition allows the company an opportunity to become a licensed producer in the province of Quebec and gain an in-road to provide tissue culture plantlets to all licensed producers in Quebec.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

On behalf of the board of directors of

ALLIANCE GROWERS CORP.

“Dennis Petke”

Dennis Petke

President and CEO

For more information contact:

Dennis Petke

Tel: 778-331-4266

DennisPetke@alliancegrowers.com

Rob Grace

Communications Consultant

Tel: 778-998-5431

RobDGrace@gmail.com

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

 

 

 


January 2, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to report that it has entered into an exclusive agreement to acquire a late stage licensed producer applicant, Biotech Canna, to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec.  Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license.

This is a key acquisition for Alliance Growers and its shareholders, as it allows the company an opportunity to become a licensed producer in the province of Quebec and gain an in-road to provide tissue culture plantlets to all licensed producers in Quebec.

There are several key points of value that are unique and advantageous to a Quebec license that include:

– 20% of Canada population is in Quebec

– Only 2 licenses have been approved in Quebec with only 1 producing (Hydropocathary).

– Quebec government has always looked to attain 25% of whatever Canada’s intentions are with business. They have publicly stated they want Health Canada to process all the licenses- 16 Applications – in Quebec and have the applications approved swiftly.

– Quebec will only purchase the supply from Quebec growers, they won’t go outside to other provinces for supply if they don’t need to.

The initial Biotech Canna facility is 10,000 sq. ft. and is attached to a 120,000-sq. ft. warehouse for expansion.  Biotech Canna will produce up to 1,000 kg per year and will increase that output in Phase 2 of expansion”.

Alliance Growers is making an initial payment of $100,000 and $150,000 in stock. Alliance Growers will acquire 100% of the Quebec late stage licensed producer applicant in stages for a total consideration of $8 Million – cash consideration of $600,000 and $7.4 Million in stock at a deemed value of $1/share, the final payment of $500,000 in Alliance stock to be released from escrow upon Health Canada ACMPR approval.

Commenting on the acquisition of a Quebec late stage licensed producer applicant, Dennis Petke, Alliance Growers’ President and CEO, stated “Management of Alliance Growers continues to carry out our mandate to build a diversified global cannabis company that will be where the market is going, not where the market is today. Alliance Growers is focused on two primary streams in the cannabis space which are the most sustainable and that are here to stay; the grow stream and the medical CBD Oil stream. To optimally drive Alliance Growers growth and stature in the grow space, we have determined that acquiring a Quebec license would be both a key driver to success and a key pillar in Alliance’ strategic business plan.”

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has finalized its a new business partnership with WFS Pharmagreen Inc., to jointly develop and operate a 40,000-square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com.

On behalf of the board of directors of

ALLIANCE GROWERS CORP.

“Dennis Petke”

Dennis Petke

President and CEO

 

For more information contact:

Dennis Petke

Tel: 778-331-4266

DennisPetke@alliancegrowers.com

 

Rob Grace

Communications Consultant

Tel: 778-998-5431

RobDGrace@gmail.com

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

 

 


December 28, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to report that it has entered into a binding Letter of Intent (“LOI”) with WFS Pharmagreen Inc. (“Pharmagreen”), and its proposed subsidiary BC New Co, to create a strategic relationship, together with equity participation by Alliance Growers and Pharmagreen, whereby Alliance Growers will acquire an equity interest in Pharmagreen’s subsidiary BC New Co (the “Proposed Transaction”).

The execution of this LOI, to be followed by a formal Definitive Agreement, initiates the development of the Cannabis Botany Centre that Alliance and Pharmagreen have been working on for over one year.  Pharmagreen principals have purchased the land required to build the Cannabis Botany Centre East of Mission, BC (the “Land”). The Land will be leased to own to BC New Co.

Alliance Growers will purchase BC New Co Shares equal to 15 % of the issued BC New Co Shares  for total consideration of $1.5 Million CDN by March 15, 2018.  Alliance Growers will have an option to increase its non-dilutive interest in BC New Co to 30% by the investment of a further $1.5 Million CDN by June 15, 2018.  Alliance Growers made an initial payment of $250,000 toward the first obligation on December 21, 2017.

Alliance Growers will elect one of the three Directors of BC New Co, which will build and operate the Cannabis Botany Centre to permit the growth and sale of tissue culture plantlets, and storage of strains and nursery plants to wholesale, retail and medical markets.

The development of the Cannabis Botany Centre is consistent with Alliance Growers business plan to be in partnership with a range of cannabis sector business opportunities including strategic investments in ACMPR licensed cannabis producers.  Alliance Growers has already acquired interests in two ACMPR applicants, most notably Canwe, a private company based in Ontario that has applied for its ACMPR license and is currently in the review and security clearance stage.

Commenting on the development of the Cannabis Botany Centre, Dennis Petke, Alliance Growers’ President and CEO, noted “We are very fortunate to be able to commence construction as soon as reasonably possible, rather than having to wait several months under the typical ACMPR application scenario.  This shortens our timeline to receive approval for an ACMPR application.

Finalizing the Pharmagreen deal is one of the most significant milestones in the Company’s business plan.  It represents the beginning of the execution of multiple initiatives that Alliance Growers has been developing over the last year.  Now that Alliance Growers has secured funding of over $1M from the recent private placement and the exercise of warrants and options, the Company will be executing on additional acquisitions of interests in ACMPR applicants, development of the Canna-App and finalization of its Pharmaceutical Grade CDB Oil partnership with the Israeli Medical Cannabis Company.  We are extremely pleased that the market has come to understand and appreciate our diversified global business model as evidenced by the strong performance in the Company’s recent stock price. The Company has already received significant interest in additional financings slated for January and February of 2018 to ensure the Company is adequately capitalized to execute on all aspects of our business model.  All stakeholders of Alliance Growers will benefit from the arrangements we are making in the cannabis cultivator space. We look forward to announcing our new complementary acquisitions and as we move forward.  Alliance Growers wishes everyone a happy, healthy and prosperous new year”.

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has finalized its a new business partnership with WFS Pharmagreen Inc., to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

On behalf of the board of directors of

ALLIANCE GROWERS CORP.

“Dennis Petke”

Dennis Petke

President and CEO

For more information contact:

Dennis Petke

Tel: 778-331-4266

DennisPetke@alliancegrowers.com

Rob Grace

Communications Consultant

Tel: 778-998-5431

RobGrace@alliancegrowers.com

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

 

 


December 20, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG) (“Alliance or “the Company”) wishes to announce that further to the Company’s news release dated December 19, 2017 wherein an announcement of a grant of 2,000,000 options was disclosed, the Company wishes to amend the exercise price from $0.43 per share to $0.46 per share.

All other terms remain unchanged.

About Alliance Growers Corp.

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments (Access to Cannabis for Medical Purposes Regulations), CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has executed an agreement with Botanical Research In Motion International Inc., for a Canada Exclusive License to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Alliance Growers has rights to 50% of BCMM, a late stage applicant that submitted its ACMPR Application to Health Canada in 2014, and is also making a strategic investment in another private Company preparing to apply for an ACMPR producer’s license. Additionally, the Company is investing in several cannabis industry participants, ranging from co-developing a Cannabis App for use by the cannabis industry and its markets, to negotiating business arrangements with several companies for the purchase and sale between the parties of live cannabis plants, tissue culture plantlets and other cannabis products and services.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com or contact:

Dennis Petke, President and CEO, Tel: 778-331-4266, Email: DennisPetke@alliancegrowers.com or Rob Grace, Corporate Communications, Tel: 778-998-5431, Email: RobDGrace@gmail.com

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.


December 19, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG) (“Alliance or “the Company”) announces that the Board of Directors has approved the grant of 2,000,000 options to directors, officers and consultants of the Company, which options are exercisable into common shares of the Company at a price of $0.43 per share.

Subject to the rules of the Canadian Securities Exchange and the Company’s Stock Option Plan, the options have a term of five years and will expire on December 19, 2022. At the time of the grant the prior days’ closing price of Alliance common shares was $0.425.

About Alliance Growers Corp.

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments (Access to Cannabis for Medical Purposes Regulations), CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has executed an agreement with Botanical Research In Motion International Inc., for a Canada Exclusive License to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Alliance Growers has rights to 50% of BCMM, a late stage applicant that submitted its ACMPR Application to Health Canada in 2014, and is also making a strategic investment in another private Company preparing to apply for an ACMPR producer’s license. Additionally, the Company is investing in several cannabis industry participants, ranging from co-developing a Cannabis App for use by the cannabis industry and its markets, to negotiating business arrangements with several companies for the purchase and sale between the parties of live cannabis plants, tissue culture plantlets and other cannabis products and services.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com or contact:

Dennis Petke, President and CEO, Tel: 778-331-4266, Email: DennisPetke@alliancegrowers.com or Rob Grace, Corporate Communications, Tel: 778-998-5431, Email: RobDGrace@gmail.com

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.


December 18, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG / FWB: 1LA / WKN: A2DFYX) (“Alliance” or “the Company”) is pleased to announce that its private placement originally announced November 20, 2017 has closed. The Company raised $833,849.83 for the issuance of 7,580,453 Units at a price of $0.11 per Unit. Each Unit is comprised of one common share and one common share purchase warrant.

Each common share purchase warrant will entitle the holder to acquire one additional common share in the capital of the Company at a price of $0.21 per share, for a period of two years from the date the Units are issued. The warrants are subject to an acceleration clause after the resale restrictions on the shares have expired. The expiry time of the warrants can be accelerated if the Company’s shares trade at or above a weighted average trading price of $0.30 per share for 10 consecutive trading days.

All securities issued pursuant to the placement will be subject to a hold period of four months and one day from the date of closing.

The proceeds from this financing will be allocated primarily to the Botany Centre for property acquisition and preliminary planning and development, plus finalization of agreements in other potentially lucrative arrangements in the medical and recreational cannabis space, as well as general working capital.

Commenting on the financing, Dennis Petke, Alliance Growers’ President and CEO said, “We are very pleased with the strong response to this recent financing. The Company expects to undertake further private placements over the next several months to fund its business plan. We are quite anxious to secure the permits for the Cannabis Botany Centre, not only to initiate our application for the ACMPR, but to begin the planning stage of the development. We would like to thank our shareholders for their continued support as we work towards realizing our vision of becoming a successful global cannabis company”.

THIS NEWS RELEASE, PROVIDED PURSUANT TO APPLICABLE CANADIAN REQUIREMENTS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION OR APPLICABLE EXEMPTION FROM REGISTRATION REQUIREMENTS

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers is finalizing a new business partnership with Botanical Research In Motion Inc., to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com.

For more information contact:

Dennis Petke, President and CEO, Tel: 778-331-4266, Email: DennisPetke@alliancegrowers.com Rob Grace, Corporate Communications, Tel: 778-998-5431, Email: RobDGrace@gmail.com

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to the use of proceeds of the Financing, as well as the Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan following the issuance of the required licenses by Health Canada. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.


Vancouver, British Columbia–(Newsfile Corp. – October 12, 2017) – Today’s buy recommendation comes from Fundamental Research Corp. Analyst Sid Rajeev gives Alliance Growers (CSE: ACG) a buy rating and a fair value estimate of $0.30 per share, a premium of 200% to the $0.10 closing price on September 27th, the day the report was issued. Alliance Growers Corp., along with it partner Botanical Research in Motion (B.R.I.M.), is planning to build a 40,000 square foot botany facility in British Columbia, Canada.

InvestmentPitch Media has produced a “video” which discusses this company. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Alliance Growers” in the search box.

Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_sacs83q2/Fundamental-Research-has-Initiated-Coverage-on-Alliance-Growers

B.R.I.M’s proprietary “Chibafreen Invitro Plant Production System” has the potential to mass-produce 3.5 million genetically superior cannabis plantlets a year, initially utilizing only 20,000 square feet. The company also expects that the botany centre will facilitate Testing Lab services, allowing Alliance to provide DNA tests for other growers in the cannabis space. Management have indicated that Alliance will initially have a 30% revenue earn-in to the botany centre at a cost of $3 million.

Analyst Sid Rajeev stated: “The botany centre will be constructed and ready to produce by the end of Q2 2018. However, as we conservatively estimate that the company’s ACMPR license will not be available until the following year, cannabis production will not commence until 2019. In the second half of 2018, we forecast Alliance will produce other plantlets with lower margins. We believe that production will double to 7 million plantlets per year once the facility is expanded. As Alliance expects there to be demand for 76 million plantlets per year, based on ACMPR licensed producers entering the market, we believe that Alliance’s market share (less than 10%) assumption is reasonable. Regarding CBD oils, management estimates an initial production capacity of 2,871liters per year. In our models, we assume production to begin at 359 liters in 2019, growing to 4,307 liters by 2024. We assume that future expansion of the production facility and joint ventures with other companies will allow CBD production capacity to increase.”

In addition to the cannabis botany centre project, Alliance also seeks to grow via strategic investments in licensed Canadian cannabis producers and is currently considering the following initiatives:

  • A planned equity investment into Canna Companion Products Inc., a wholly owned subsidiary of WFS PharmaGreen Inc., that produces and sells hemp-based pet supplements. As part of the arrangement, Alliance would invest $300,000 into Canna, and receive exclusive long-term CBD oil supply contracts when Canna expand into the Canadian market.
  • Alliance has closed the first tranche of its equity investment into New Maple Holdings Ltd., the parent company of Canwe, an Ontario-based cannabis grower applying for an ACMPR license.
  • Alliance maintains a 50% stake in BC Maramed Production, an ACMPR license applicant, that owns a leasehold interest and equipment to outfit a 11,000 square-foot growing facility in Kelowna, British Columbia.
  • Alliance has entered discussion with an undisclosed private cannabis company in Ontario to acquire a non-dilutive 10% ownership stake.
  • Furthermore, Alliance is considering a joint venture with an Israeli medical marijuana company to develop pharmaceutical grade CBD oil, which could significantly impact Alliance’s future CBD oil business. Growth in this side of the business could imply significant future profits, as the cannabis-infused products segment of the cannabis industry exhibits impressive potential for profitability.

Alliance Growers’ management team and board of directors have significant legal and cannabis industry expertise, as demonstrated by their track records. Management owns 7.5% of the outstanding shares.

The shares are trading at $0.12, well below Fundamental’s fair value price of $0.30, and with 41.7 million shares outstanding, the company is capitalized at $5.0 million.

For more information please visit the company’s website www.alliancegrowers.com, contact Dennis Petke, President and CEO, at 778-331-4266, or email DennisPetke@alliancegrowers.com.

About InvestmentPitch Media

InvestmentPitch Media is arguably the largest producer and distributer of video news content, primarily for small and mid-cap companies. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

 


October 13, 2017 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to report that the Company has commenced the ACMPR application with its partner Botanical Research In Motion International Inc. (“BRIM”).  Alliance and BRIM will begin construction of the Cannabis Botany Centre within the next 6 to 8 weeks, weather permitting.  Because the facility is a Botany Centre and can be used to propagate tissue culture plantlets for almost any plant, the Company will not have to wait several months to begin construction as is often required under the ACMPR application process.

Alliance has already acquired interests in two ACMPR applicants, most notably Canwe, a private company based in Ontario that has applied for its ACMPR license and is currently in the review and security clearance stage.  Along with the multiple financing mechanisms in place, ready to go Alliance is working to complete on the next tranches of our investment in Canwe.

“We are very fortunate to be able to commence construction as soon as reasonably possible, rather than having to wait several months under the typical ACMPR application scenario.  This shortens our timeline to receive approval for an ACMPR application.  In addition to the BRIM ACMPR, we are very our interest in Canwe, a strong ACMPR applicant, will become a valuable asset once Canwe is approved for their ACMPR license.  All stakeholders of Alliance will benefit from the arrangements we are making in the cannabis cultivator space.  We look forward to announcing our new acquisitions in the coming weeks.” said Dennis Petke, Alliance Growers’ President and CEO.

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers is finalizing a new business partnership with Botanical Research In Motion Inc., to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

On behalf of the board of directors of

ALLIANCE GROWERS CORP.

“Dennis Petke”

Dennis Petke

President and CEO

For more information contact:

Dennis Petke

Tel: 778-331-4266

DennisPetke@alliancegrowers.com

Rob Grace

Communications Consultant

Tel: 778-998-5431

RobGrace@alliancegrowers.com

 

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

 

 


Dear Shareholders, stakeholders and potential investors,

We are very pleased to announce that Alliance Growers has met the criteria to be listed as part of the CSE Composite index.  Effective September 15, 2017 Alliance Growers was brought into the CSE Composite index as part of the CSE’s Quarterly Rebalancing. http://thecse.com/en/trading/market-activity/cse-indexes

Alliance had had an incredible year thus far and we expect to end the calendar year at an all-time high.  This year we were able to more clearly define our business model and we identified the best paths to maximize value for all shareholders and stakeholders.

I would like to open up with clarification about our analyst coverage in a recent news release dated October 3, 2017.  We announced that Fundamental Research Corp. (“FRC”) published an initial equity analyst research report on Alliance Growers.  In accordance with IROC disclosure requirements, Alliance was required to disclose the amount paid to FRC.  In error, the news release read that Alliance Growers paid $25,000 for the report.  This was a significant misstatement as Alliance has never paid for any reports, especially an independent report.

Alliance Growers did, however, pay FRC $25,000 for one year of analyst coverage which includes Continuous Analyst Coverage for a duration of one year, starting with the initiating report, consisting of broad distribution of 4 Reports, and Analyst Notes featured on top Global Institutional and Retails Portals. In additional to global exposure, Fundamental Research will be representing ACG at various Industry Investment Conferences throughout North America and Europe at no additional cost. The most recent being the CSE sponsored event “Cannabis In The Capital Markets”, September 26, 2017 in Kelowna BC.

The Alliance Objective

We at Alliance are working to build a global cannabis company that will be where the market is going, not where the market is now, as it is constantly evolving.  We are focused on two primary streams in the cannabis space which are the most sustainable and that are here to stay; the grow stream and the medical CBD Oil stream.  We have other ancillary projects that complement the two main focus areas, but these two are our main focus.

The team continues to research and stay on top of the market for tissue culture plantlets as that business in Canada alone will be significant.  We expect to bring it to Europe next, starting with Germany as they started taking grow applications in June of 2017 for the first time ever.  Investors should note that although tissue culture is not new in general, it is new to the cannabis space to a certain extent and we have access to a better proprietary method through our partnership with BRIM.  It should also be noted that the barriers to entry are high as the qualification for the main staff and even assistants are extremely high and the initial facility cost and ongoing operating costs including quality control, are high.  This means that it is not worth it for individual growers, (even large ones like Aurora) will be doing tissue culture in house anytime soon.  Alliance is working on an extension to the Cannabis Botany Centre model, to provide in-house services where it makes economic sense for all parties.

Botanical Research in Motion Inc. (“BRIM”),

The Company and its business partner, BRIM have begun the process for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) application with Health Canada, now that the property for the Cannabis Botany Centre has been secured.  The ACMPR Application will initially be for the 40,000 square foot Cannabis Botany Centre, however expansion plans will include a combination of greenhouse and indoor grow facilities of up to 1 million square feet on the 25 acre farm land acquired in Dewdney Derouche, Mission, BC, Canada.

BRIM and Alliance Growers will be working together to finance the construction of the Cannabis Botany Centre facility on the 25.44 acres of land located at 38482 Bell Road, Dewdney Derouche, Mission, BC, with some of the best water quality in the Greater Fraser Valley. This property has R-3 zoning to be converted to ALR and is located in the Fraser Valley Agricultural Belt, just 75 minutes East of Vancouver.

ACMPR Applicants

The Company is in negotiations with several ACMPR applicants at various stages in British Columbia and in Eastern Canada to acquire significant interests in their operations, via a shared financing mechanism. Due to the uncertainty with Canadian Public companies acquiring US cannabis related assets, Alliance has made the decision to focus on Canadian applicants at this time.

Alliance has already acquired interests in two ACMPR applicants, most notably Canwe, a private company based in Ontario that has applied for its ACMPR license and is currently in the review and security clearance stage. Canwe’s experienced team in cultivation and regulation presents a unique competitive advantage to Alliance Growers as we negotiate with other ACMPR applicants.

Canwe has access to a 22-acre property approximately 1.5 hours away from Toronto that it plans to use as its state-of-the-art hydroponic growing facility. Canwe boasts a strong team of highly sought-after industry veterans, some of whom formerly worked at ACMPR-licensed MedReleaf Corp. (TSE: LEAF). The team also includes several University of Toronto alumni and quality assurance specialists from the food industry. Canwe plans to construct an initial 80,000 square foot purpose-built and cutting edge cultivation centre, with the potential to expand the centre to 200,000 square feet over two floors.

The number of ACMPR applicants in Canada has increased drastically over the past several months as the regulations make for faster license processing for the best prepared candidates. The company has been in talks with growers from Vancouver Island and throughout the Okanagan, most recently working with a private ACMPR Applicant building a 100,000 square foot facility in Summerland.

International distribution of Medical CBD Oil

Alliance has entered into advance discussions with an Israeli medical cannabis company to make a strategic investment for a 20% equity interest in their company.  The Israeli company will grow and extract cannabis flower to develop pharmaceutical grade cannabidiol oil (CBD Oil).

The company is making an initial investment in phase 1 of their overall plan of USD$4.8M which is designated for 50-Hectares of site development, establishment of a mother nursery and a commercial greenhouse located in the most suitable area for Cannabis cultivation in the low cost off-shore jurisdiction. Alliance is in constant communication with the principals and when the Israeli company is ready for us, we will be ready for them, as we have been lining up financing for the CAD$2M investment with European institutions.

It is anticipated that the majority of the plant production would be processed for the extraction of pharmaceutical grade CBD Oil. This would facilitate the importation of the CBD Oil into various parts of Europe as it opens, then certain states in the USA and Canada when legalized.

The Israeli company has extensive expertise cultivating world-class marijuana in technical greenhouses. They have a team of scientists, designers, and engineers committed to developing high quality medial cannabis using greenhouses in geographical locations that offer an abundance of natural light. The Company’s R&D is based in Israel and involves both scientific and academic research as well as current ongoing registered medical clinical studies.

The Hemp Business Journal reports that the CBD market is growing at a rate of 30% per annum, and forecasts that sales of CBD Oils from marijuana-based sources are expected to reach $1,650,000,000, or- 79% of the Total CBD Market of $2,100,000,000 by 2020.

Financing Initiatives

Private Placement 3.8M units at 11c

Earlier this year, Alliance announced a non-brokered private placement to issue up to 3,800,000 Units at a price of $0.11 per Unit to raise gross proceeds of up to $418,000. Each Unit is comprised of one Share and one Warrant.  One Warrant is exercisable into one additional Share for a period of two years from the Closing Date at a price of $0.21 per Warrant share.

We are closing another $100k of the 11c private placement soon and we will be pricing another one higher in the coming weeks as the market moves up.

European Financing

The Company has received consideration from European financing groups for funding.  We have resumed discussions and are negotiating more favourable terms now that the institutions have a research report to better understand the potential of our business model.

Alliance Growers has been approached by a respected, experienced European investment group with an offer of multiple financing options on favourable terms that are optimally triggered by the various stages of the Company’s current and future needs, to prevent dilution to existing shareholders. The most significant benefit of the potential engagement is the introduction to key strategic investors. For example, this particular group has the ability to make introductions to strategic investors who are already involved in the cannabis space in Europe, such as CDB oil distribution in Germany.

Alumina Partners

Approximately three months ago, we executed on the first tranche of a financing commitment from Alumina Partners (Ontario) Ltd., a subsidiary of Alumina Partners LLC, a New York-based private equity firm, for a $5 Million equity facility in a series of private placements, with an option to extend the commitment up to $10 million. The Company proceeded with the first tranche of the offering by issuing 1,000,000 units at an issuance price of 10.5 cents per unit, each unit consists of one common share and one share purchase warrant, exercisable at $0.21 per share for a period of five years.

The purpose of the Equity Facility is to provide the Company with continuous funding for working capital and for its integrated projects at progressive intervals that are consistent with the value of the Company at each stage of its development and growth.

I am in communication with Alumina on a weekly basis and they are ready to finance us for another tranche anytime we are ready.  When our stock price moves up to 15 cents or higher, we will execute on another tranche for working capital purposes.

Other Financing initiatives

To assist in the financing of ACMPR applicants, we have developed a unique financing mechanism working with those who want to invest in private ACMPR applicants, but who also would like to reduce their risk and enjoy liquidity. To do so, these investors invest through Alliance with the bulk of the proceeds being used to acquire an interest in the private applicant, thus giving them the funds they require to proceed with their applications and subsequent operations.

Fundamental Research – initiating coverage

The independent research report dated September 28, 2017, entitled “Alliance Growers Corp. (CSE: ACG): Cannabis Company Developing Cutting Edge Production Facility – Initiating Coverage” was written and produced by FRC’s Vice-President and Head of Research, Siddharth Rajeev, B.Tech, MBA, CFA, as an independent analysis of ACG’s activities and progress.  Alliance Growers does not endorse the recommendations and contents of the research report, nor does it confirm that the disclosures contained in the research report are compliant with CSE policy 5 and applicable securities regulations.

The FRC report is currently available to view, or to download by members, from FRC’s website – www.researchfrc.com or upon written request from FRC:

All reports on Alliance Growers prepared by analysts represent the views of such analysts and are not necessarily those of Alliance Growers. Although the Company has paid a fee to Fundamental Research Corporation to provide its independent research opinion (just as fees are paid to bond-rating agencies and auditors for their opinions), the Company is not responsible for the content, accuracy or timelines contained in an analyst’s report and the fee was not dependent on the opinion provided.

About Alliance Growers

Alliance Growers Corp is a diversified cannabis company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Development.

Alliance Growers has executed an agreement with Botanical Research In Motion International Inc., for a Canada Exclusive License to jointly develop and operate a 40,000 square foot facility to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Botany Centre will grow Cannabis plantlets using proprietary tissue culture propagation, specifically the “Chibafreen Invitro Plant Production System”, which assures consistent composition and purity of each plantlet for the growers.

Further, Alliance Growers has been negotiating to obtain other exclusive Canadian distribution agreements for certain proprietary products for support of the Cannabis growing industry in addition to possible partnerships with Licensed Producer Applicants at various stages in the Health Canada License process.

For further information, please visit the Company’s corporate website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.

If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com

On behalf of the board of directors of

ALLIANCE GROWERS CORP.

“Dennis Petke”

Dennis Petke

President and CEO

For more information contact:

 Dennis Petke

Tel: 778-331-4266

DennisPetke@alliancegrowers.com

 Rob Grace

Corporate Communications Consultant

Tel: 778-998-5431

RobDGrace@gmail.com